4Tissue is pleased to announce that Dr. Benoit Moreaux has joined the company’s leadership team as Chief Executive Officer (CEO).
Dr. Benoit Moreaux brings an extensive research & development, manufacturing, regulatory and clinical development track record from his senior roles at J&J, Baxter, Nikkiso Belgium, Bone Therapeutics, Bio-Sourcing and 2Bridge.
This appointment further strengthens 4Tissue’s company building towards a clinical stage company.
Phillip Blondeel, MD., co-founder and clinical advisor of 4Tissue. “We have embraced an avant-garde methodology, marrying the capabilities of biocompatible polymers with a patient’s own stem cells. This pioneering strategy facilitates the introduction of a holistic and natural alternative for breast tissue replacements, catering to diverse needs—from cosmetic augmentations to vital reconstructions following medical procedures such as tumorectomies, mastectomies, and even rectifying congenital deformities.”
Sandra Van Vlierberghe, PhD., co-founder and scientific advisor of 4Tissue. “As a company distinguished for our advancements in bioresorbable hydrogels, 4Tissue stands at the forefront of innovation within the breast tissue replacement industry. Benoit’s broad experience in product development, QA/QC and regulatory affairs in medical device and ATMP products are important capabilities to drive 4Tissue's trajectory towards clinical development.”
An Van Den Bulcke, PhD., co-founder and Chief Business Officer of 4Tissue. “I am grateful that Benoit has recently joined our company as we are progressing to the next stage of securing series A funding. As we embark on this promising chapter of first-in-human studies, the entire 4Tissue team beams with anticipation.”
Benoit Moreaux, DVM, PhD, PMP, has substantial pharma, medtech and ATMP experience and in-depth knowledge of clinical trajectories, including certification, manufacturing via CMOs and Clinical Trial Application submissions. He has held senior positions at J&J, Baxter, Nikkiso Belgium, Bone Therapeutics, Bio-Sourcing and 2Bridge. His illustrious career is marked by a steadfast commitment to leadership and an acute understanding of the lifescience industry nuances.